Myeloid Growth Factor Therapy for Prophylaxis of Febrile Neutropenia in Non-Myeloid Malignancies: Appropriate Doses and Schedules

Author： Althaus Betsy L.  

Publisher： Cambridge Scholars Publishing in association with GSE Research

ISSN： 1540-1405

Source： Journal of the National Comprehensive Cancer Network (JNCCN), Vol.5, Iss.2, 2007-02, pp. : 229-234

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Pharmacokinetics of Darbepoetin Alfa after Intravenous or Subcutaneous Administration in Patients with Non-myeloid Malignancies Undergoing Chemotherapy

By Heatherington Anne C.  

Clinical Pharmacokinetics, Vol. 45, Iss. 2, 2006-01 ,pp. : 199-211

Adis International

Access to resources Recommend Favorite

Voriconazole: appropriate empirical therapy in febrile neutropenia?

By  

Inpharma, Vol. 1, Iss. 1323, 2002-01 ,pp. : 8-8

Adis International

Access to resources Recommend Favorite

Panobinostat in lymphoid and myeloid malignancies

By Khot Amit   Dickinson Michael   Prince H Miles  

Expert Opinion on Investigational Drugs, Vol. 22, Iss. 9, 2013-09 ,pp. : 1211-1223

Informa Healthcare

Access to resources Recommend Favorite

Pegfilgrastim fits the bill for febrile neutropenia prophylaxis in Europe

By  

Inpharma, Vol. 1, Iss. 1566, 2006-01 ,pp. : 5-6

Adis International

Access to resources Recommend Favorite

G-CSF as prophylaxis of febrile neutropenia in SCLC

By Feinglass Joe   Adams Jared R   Djubegovic Benjamin   Bennett Charles L   Lyman Gary H  

Expert Opinion on Pharmacotherapy, Vol. 3, Iss. 9, 2002-09 ,pp. : 1273-1281

Informa Healthcare

Access to resources Recommend Favorite